BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of targeted therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has a strategic collaboration with Celgene Corporation to research and develop BeiGene, Ltd.'s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317; and with Merck KGaA to research and develop on BGB-290 and BGB-283. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BGNE
CUSIPN/A
Phone34-59-494-12
Debt
Debt-to-Equity Ratio0.12
Current Ratio11.18
Quick Ratio11.12
Price-To-Earnings
Trailing P/E Ratio-75.66
Forward P/E Ratio-19.32
P/E GrowthN/A
Sales & Book Value
Annual Sales$238.39 million
Price / Sales37.95
Cash FlowN/A
Price / CashN/A
Book Value$15.02 per share
Price / Book11.20
Profitability
EPS (Most Recent Fiscal Year)($2.23)
Net Income$-93,100,000.00
Net MarginsN/A
Return on Equity-19.12%
Return on Assets-13.75%
Miscellaneous
Employees900
Outstanding Shares53,760,000
BeiGene (NASDAQ:BGNE) Frequently Asked Questions
What is BeiGene's stock symbol?
BeiGene trades on the NASDAQ under the ticker symbol "BGNE."
How were BeiGene's earnings last quarter?
BeiGene (NASDAQ:BGNE) posted its quarterly earnings data on Wednesday, May, 9th. The company reported ($2.03) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.62) by $0.41. The business earned $32.54 million during the quarter, compared to analyst estimates of $16.88 million. During the same quarter in the prior year, the company posted ($1.27) earnings per share. View BeiGene's Earnings History.
When is BeiGene's next earnings date?
What price target have analysts set for BGNE?
8 brokers have issued twelve-month price targets for BeiGene's stock. Their predictions range from $86.00 to $225.00. On average, they expect BeiGene's stock price to reach $170.1667 in the next year. View Analyst Ratings for BeiGene.
What are Wall Street analysts saying about BeiGene stock?
Here are some recent quotes from research analysts about BeiGene stock:
- 1. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (6/13/2018)
- 2. Maxim Group analysts commented, "BeiGene announced the commercial availability of Celgene’s VIDAZA. Recall that VIDAZA is an injectable nucleoside metabolic inhibitor for patients with Intermediate-2/high-risk myelodysplastic syndrome (MDS), AML with 20-30% bone marrow blasts and chronic myelomonocyte leukemia (CMML). The asset is the third product in BeiGene’s China commercial portfolio along with Abraxane and Revlimid and positions BeiGene to be a leader in the oncology space in China." (2/7/2018)
Who are some of BeiGene's key competitors?
Some companies that are related to BeiGene include Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY) and Perrigo (PRGO).
Who are BeiGene's key executives?
BeiGene's management team includes the folowing people:
- Mr. John V. Oyler, Founder, Chairman and Chief Exec. Officer (Age 50)
- Dr. Xiaodong Wang, Co-Founder, Chairman of the Scientific Advisory Board and Director (Age 55)
- Dr. Heng Liang Ph.D., Chief Financial Officer and Chief Strategy Officer (Age 55)
- Mr. Ji Li Ph.D., Exec. VP & Global Head of Bus. Devel. (Age 50)
- Ms. Maggie Liu, Head of Operations and VP
When did BeiGene IPO?
(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.
Has BeiGene been receiving favorable news coverage?
Media coverage about BGNE stock has been trending somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BeiGene earned a media sentiment score of 0.24 on Accern's scale. They also gave news headlines about the company an impact score of 47.95 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are BeiGene's major shareholders?
BeiGene's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Temasek Holdings Private Ltd (4.22%), Artal Group S.A. (1.12%), OppenheimerFunds Inc. (1.07%), Indus Capital Partners LLC (1.05%), BlackRock Inc. (0.66%) and Prince Street Capital Management LLC (0.57%). Company insiders that own BeiGene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler, Thomas Malley and Xiaodong Wang. View Institutional Ownership Trends for BeiGene.
Which institutional investors are selling BeiGene stock?
BGNE stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Bellevue Group AG, DAFNA Capital Management LLC, Prince Street Capital Management LLC, Rock Springs Capital Management LP, State of New Jersey Common Pension Fund D, The Manufacturers Life Insurance Company and Employees Retirement System of Texas. Company insiders that have sold BeiGene company stock in the last year include Amy C Peterson, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler and Xiaodong Wang. View Insider Buying and Selling for BeiGene.
Which institutional investors are buying BeiGene stock?
BGNE stock was purchased by a variety of institutional investors in the last quarter, including Temasek Holdings Private Ltd, Artal Group S.A., KEYWISE CAPITAL MANAGEMENT Ltd, Indus Capital Partners LLC, Matthews International Capital Management LLC, Barings LLC, Hsbc Holdings PLC and Ariose Capital Management Ltd. Company insiders that have bought BeiGene stock in the last two years include Bros Advisors Lp Baker and Thomas Malley. View Insider Buying and Selling for BeiGene.
How do I buy shares of BeiGene?
Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BeiGene's stock price today?
One share of BGNE stock can currently be purchased for approximately $168.29.
How big of a company is BeiGene?
BeiGene has a market capitalization of $8.88 billion and generates $238.39 million in revenue each year. The company earns $-93,100,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. BeiGene employs 900 workers across the globe.
How can I contact BeiGene?
BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 34-59-494-12 or via email at [email protected]
MarketBeat Community Rating for BeiGene (BGNE)
MarketBeat's community ratings are surveys of what our community members think about BeiGene and other stocks. Vote "Outperform" if you believe BGNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BGNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
